News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
The deal covers distribution of certain of Primerdesign's molecular testing products to the aquaculture and aquamarine markets in France.
The test adds to a menu of transplant monitoring assays that includes cytomegalovirus, Epstein-Barr virus, and BK virus.
The new test increases the multiplexing of the sepsis panel from 26 targets to 43 targets, including seven additional resistance genes.
Analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4 and $116.4 million in full-year 2019 revenues.
